Novo Nordisk Resets to Peer-Level Growth of Mid-Single Digits Through 2030, Betting on Oral Wegovy Scale and a DKK 150 Billion Risk-Adjusted Pipeline
Capital Markets Day in London, September 21, 2026: management ties a stable operating margin to a 10x oral capacity build and a broader pipeline, while declining to guide 2027
Novo Nordisk used its Capital Markets Day to put a number on the post-hyper-growth era. CFO Karsten Knudsen said the industry is growing at a mid-single-digit CAGR from this year to 2030 and that Novo aims to match that pace. The company more than doubled in four years, tripled R&D and scaled CapEx 10x, and Knudsen acknowledged that "unfortunately, growth has come down." The pledge is therefore a ceiling on near-term expectations as much as a commitment. Management said the operating margin should be broadly stable by 2030, with possible annual fluctuations, and it declined to guide 2027 until February. CEO Maziar Doustdar was blunt about the setup: "We are incredibly convicted that there is a bright future for Novo. But we also realize that it's not enough for us to be convicted. We have to convince you."
The growth algorithm: three drivers, a deliberately modest number
Knudsen identified three sources of growth. The first is the Wegovy pill, with 1.5 million patients today and manufacturing being built for 10x that number by 2030. The second is a string of diabetes and obesity launches: CagriSema (FDA decision expected in the fourth quarter, launch early 2027), cagrilintide monotherapy in 2028, high-dose CagriSema a year later, and zenagamtide later in the period. The third is blockbuster launches outside the core, namely Frehemgo in hemophilia, etavopivat in sickle cell disease and, late in the decade, efruxifermin in liver disease. Price erosion and loss of exclusivity in some markets offset part of this. Asked whether the mid-single-digit figure was conservative, Knudsen said management ran scenarios on price elasticity, volume and realistic pipeline uptake, and called the outcome "reasonable."
Doustdar added that the CAGR is not a straight peer average and should be read as "at least on par" over four to five years. He said he is more optimistic on CagriSema than consensus. Analysts at the event noted that 2026 has delivered no growth, and management was candid that the US Ozempic franchise faces IRA-related pricing in 2027. Novo has assumed price declines of roughly 10% a year for GLP-1s.
Margin math: gross margin held, SG&A trimmed, R&D grows faster than sales
The margin plan is a trade between functions. Gross margin, around 80% today, is to stay broadly stable, with pricing and CapEx depreciation offset by yield gains, new formulation generations and network optimization. Knudsen said mix is not a meaningful headwind because the Wegovy pill's margin is "reasonably close to group average." He added that CagriSema will be too small early on to dent the group margin. SG&A, which fell from 29% to 23% of sales over four to five years, is to approach the industry level of about 20% while rising in absolute terms. R&D, which rose from just under 13% to 17% of sales, is to keep outgrowing revenue. CapEx peaked last year and falls below DKK 55 billion this year, trending toward mid-single-digit percent of sales by 2030. Headcount is down 13,000 from a year ago. Capital returns have totaled DKK 270 billion over five years, with a dividend payout of roughly half of profits and net debt/EBITDA of 0.7x at year-end 2025.
Orals as the moat: manufacturing, SNAC and patents
Manufacturing chief Kasper Mejlvang argued that Novo's structural advantage is concentrated in oral peptides. He said its continuous yeast-fermentation process makes it "by far the most cost-effective producer in the industry" versus synthetic peptide routes. He declined to quantify the gap but said it is not small. The API ramp in Clayton delivered 5x design capacity last year and is on track for more than 6x this year. A first Kalundborg line is validated, a tablet site in Athlone, Ireland was acquired, and Durham is scaling up. Knudsen added that the barrier is highest in tablets, given the API volumes, CapEx and formulation patents required. The amylin compound patent runs to late 2037, which supports CagriSema's durability beyond the semaglutide cliff.
Wegovy pill launch data: market-leading, but the channel is cash
US leadership said the pill is averaging about 285,000 weekly TRx against roughly 45,000 for the oral competitor, with more than 80% of oral new-to-brand scripts. Oral products already account for about one-third of the obesity prescription market, and 80% of Wegovy pill patients are GLP-1 naive. About 90% of pill sales are self-pay, which Doustdar called a striking shift. "Who would have thought just a few years back that 90% of our Wegovy pill sales will go through a cash channel in the U.S.?" The cash channel is less profitable and more labor-intensive, which is why Novo is rebuilding NovoCare with lower cost to serve. A subscription model with telehealth partner Ro has 55,000 active subscribers. In the first four months these patients filled four prescriptions versus three for a matched non-subscriber cohort, and more than half are titrating to the 9 mg or 25 mg strengths. Weekly Wegovy franchise share has recovered by about 8 points since January, yet US obesity sales fell 4% at constant exchange rates in the second quarter on mandated and commercial price pressure. Only 35 of every 100 new-to-brand GLP-1 obesity scripts get filled, and the US list price for Ozempic, Wegovy and Rybelsus drops to $675 in 2027.
Loss of exclusivity: price down, volume up, and a bet on segmentation
Doustdar did not dismiss the cliff. He expects a step-down in price in 2031-32, more broadly than the early LOE markets. He argued that markets expand when prices fall: "the price might go down by 50%, but there is much more higher volume availability than doubling up to breakeven and even more so." Executives pointed to human insulin as the proxy for a long tail of low-priced standard of care. They said the real defense is moving patients to CagriSema, the oral and next-generation assets before 2031. The company said it is more exposed outside the US to share pressure: its volume share in once-weekly GLP-1s fell about 7 points in 12 months to roughly 52%, with the low point a year ago. International Operations head Emil Larsen said Novo now captures about 40% of share of growth, with Europe and Canada above their market share, though other regions remain under pressure.
Pipeline: CagriSema repositioning, early differentiation, and no Phase I data
R&D head Martin Lange was candid that Novo has little Phase I data to show, since it had only three first-in-human doses last year. It is at five this year and expects at least 10, potentially 15 to 16, then at least 15 a year from next year and more than 20 beyond 2030. He set a goal of five years or less from first-in-human to submission in diabetes and obesity and said some of this year's assets could launch around 2030.
On CagriSema, the company leaned on individualized dosing. REDEFINE 9 showed about 21% weight loss at the 1 mg dose. In diabetes, REIMAGINE 5 showed 12.5% weight loss with CagriSema 1 mg versus about 9% for tirzepatide 5 mg at the same glycemic control. Analysts challenged how this will be positioned against headline REDEFINE results showing inferiority to the competitor, and management said label inclusion depends on regulators. A Phase II neuropathic pain study (70 patients per arm) showed a 2.4-point reduction on a 10-point scale, or 1.2 points placebo-adjusted, versus 0.5 to 1 point for gabapentinoids, and Phase III trials start this year. Lange also described a once-monthly GLP-1 and amylin effort, an ALK7 program aimed at muscle preservation, an ACSL5 inhibitor with double-digit weight loss in animal models without titration, a thermostable and high-yield oral GLP-1 for affordability, and oral amylin 355 in Phase II. Zenagamtide will be filed as a BLA.
Diversification: blood, liver and CV, with a candid ZEUS caveat
Blood and endocrine is targeted to grow by more than 50% from 2026 to 2030. Frehemgo for hemophilia A received a positive CHMP opinion and awaits an FDA response. Etavopivat in sickle cell disease reduced vaso-occlusive crises by 27% and showed a nearly 50% hemoglobin response, with a filing planned by year-end. In liver disease, efruxifermin is aimed mainly at F4 cirrhosis, where no treatment exists. Lange said "the true value" lies there, and he acknowledged bone density signals that keep Novo from pushing earlier into F3. In cardiovascular disease, Lange was unvarnished on ZEUS: "we saw absolutely nothing. So the hazard ratio was 0.99." Novo continues with ziltivekimab in ARTEMIS, an oral IL-6, NLRP3 inhibitors and the TTR depleter coramitug. It also plans a GLP-1 plus oral PCSK9 combination, with Phase I starting next year.
Targets and accountability: DKK 150 billion, but the AI story is early
Management set at least five multi-blockbuster launches by 2030, with at least 10 Phase III launches (five in the core and five elsewhere). It also set a risk-adjusted pipeline of more than DKK 150 billion in sales by 2035, excluding business development and Consumer Rx. The company aims to serve more than 60 million patients, up from 46.5 million. Consumer Rx, a prescription-to-consumer play, is described as a smaller bet with eight Phase II programs planned across new areas, including addiction. On AI, the head of R&D AI, Mishal Patel, cited a threefold improvement in target hit rate and a 500-fold potency gain in a once-monthly amylin campaign within three rounds and about 2,000 molecules. Management acknowledged that the gains are preclinical so far, and that clinical productivity gains are yet to be shown. On M&A, Doustdar did not rule out a large deal but said the strategy remains bolt-ons.